RLMD
RELMADA THERAPEUTICS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 9 Relmada Therapeutics announced a $160 million PIPE financing through…
- Mar 19 ▲ Relmada Therapeutics reported financial results for 2025 and provide…
- May 13 ▼ Relmada Therapeutics filed an automatic shelf registration statement…
- Jun 18 HC Wainwright & Co. initiates
- Sep 9 to Sep 10 ▲ 2 days of insider buys: $1.7M by 2 insiders, avg $4.18
- Sep 11 ▲ RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchas…
- Nov 12 ▲ Earnings: RLMD Q3 2026 Earnings: EPS $-0.12 (+18.9% vs est)
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $1.7M at an average $4.18. No open-market sales. Price is 14% below their cost.
- InstitutionsBULLISH
Q3 2026: 21 added (0 new), 8 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.162 → −$0.125 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −11.0% to 10.84M shares. 6.4 days to cover, ≈10.2% of shares.
- TrendRANGE
4% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $12.5M |
| Qube Research & Technologies Ltd | DOUBLED | $7.2M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $4.5M |
| Walleye Capital LLC | ADD | $3.8M |
| MARSHALL WACE, LLP | TRIM | $2.3M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $1.9M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $1.6M |
| UBS Group AG | DOUBLED | $1.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jun 2026Price is below the lowest target. Median implies +205%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 18, 2026 | HC Wainwright & Co. INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Shenouda Maged Chief Financial Officer Sep 10, 2026 | BUY | $339.1K |
TRAVERSA SERGIO Chief Executive Officer Sep 10, 2026 | BUY | $410.0K |
Shenouda Maged Chief Financial Officer Sep 9, 2026 | BUY | $504.8K |
TRAVERSA SERGIO Chief Executive Officer Sep 9, 2026 | BUY | $418.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.13 | -$0.15–-$0.09 | +20.6% | $0.00 |
| Next Q | -$0.14 | -$0.18–-$0.11 | +12.1% | $0.00 |
| Current FY | -$0.41 | -$0.41–-$0.41 | -13.9% | $0.00 |
| Next FY | -$0.41 | -$0.41–-$0.41 | +10.9% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 3 press releases · 1 bullish · 2 bearish · 5 neutral- BEARISH SC 13G/ANov 16, 2026
Squadron Capital Management LLC filed an amended Schedule 13G disclosing a 3.3% passive stake in Relmada Therapeutics as of September 30, 2026, representing 3,500,000 shares. The filing confirms a reduction from a prior 5%+ position, as Squadron is now below the 5% threshold and has exited its…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 16, 2026
Relmada Therapeutics appointed Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer, Urology & Uro-Oncology, effective November 16, 2026. Dr. Jakobsen previously led the global clinical development program for ADSTILADRIN at Ferring Pharmaceuticals and will oversee Relmada's pipeline…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Relmada reported Q3 2026 net loss of $13.9M ($0.12/share), wider than the $10.1M loss in Q3 2025…
The key catalyst is the year-end 2026 IND submission for NDV-01; any delay or FDA feedback will drive the next significant move. The 18-month durability data is supportive but preliminary. Monitor…
- BULLISH CLUSTERSep 11, 2026
RLMD CEO Sergio Traversa and CFO Maged Shenouda collectively purchased $1.67M of stock in…
CEO/CFO cluster buys at RLMD are the strongest insider signal in the dataset per academic literature. With the stock near $4.10-4.25 and institutional holders like Jupiter Topco ($77M) already in…
All RLMD filing & press-release reports (11)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 16, 2026
- 8-K reportNov 12, 2026
- CLUSTER reportSep 11, 2026
- S-3ASR reportMay 13, 2026
- 8-K reportMay 12, 2026
- DEFA14A reportApr 17, 2026
- S-3 reportApr 3, 2026
- PRESS-RELEASE reportMar 19, 2026
- PRESS-RELEASE reportMar 12, 2026
- PRESS-RELEASE reportMar 9, 2026